Navigation Links
Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer

ALBUQUERQUE, N.M., Feb. 17 /PRNewswire/ -- Exagen Diagnostics, Inc., which provides proprietary molecular diagnostics testing services, genomic probes for research and analytic specific reagents to clinical laboratories and academic institutions, today announced that John Alsobrook, Ph.D., has been named vice president and chief operating officer. In his new role, Alsobrook oversees Exagen's day-to-day operations, company alliances and genomic marker discovery and development programs. He reports to Exagen Founder and Interim CEO Waneta Tuttle, Ph.D., M.B.A.

Alsobrook joined Exagen in 2006 as the company's director of genomic marker discovery, responsible for quality control and analysis of genomic data using both standard statistical approaches and Exagen's proprietary data mining engine. He played a key role in the development of the company's initial prognostic marker test that identifies the risk of recurrence in certain breast cancer patients. Alsobrook has also led the company's development of diagnostic tests for patients with gastroenterological conditions such as irritable bowel syndrome and inflammatory bowel disorder.

"John's extensive background in genomic science has provided Exagen with invaluable insight as the company develops new products and services for clinical laboratories and academic institutions," said Dinesh Patel, Ph.D., Exagen board chairman and managing director at investment firm vSpring Capital. "His experience and proven leadership skills make him a key member of the management team that will lead Exagen into the next phase of growth," Patel added.

Alsobrook has nearly 30 years of industry and faculty experience in scientific management, research and project consulting. Prior to joining Exagen, he worked as a consultant for clients including Genaissance Pharmaceuticals, Amersham Health, G.E. Healthcare and Massachusetts General Hospital. Alsobrook also worked at CuraGen Corp. as genetics supervisor for drug discovery and as senior research scientist for pharmacogenomics. From 1996-2000, Alsobrook was associate faculty scientist at Yale School of Medicine Child Study Center, where he investigated inherited psychiatric disorders. He holds B.S. degrees in biochemistry and physics from California State University Los Angeles, and both an M. Phil. and a Ph.D. from Yale University's Department of Genetics.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is a CLIA-registered molecular diagnostics laboratory with a growing menu of proprietary, internally developed genomic tests. Exagen also sells genomic probes for research use and analyte specific reagents to other clinical laboratories and academic institutions. For more information, visit

SOURCE Exagen Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
2. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
3. Hypertension Diagnostics Announces Fiscal Year 2007 Results
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
7. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
8. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
9. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
10. Quest Diagnostics Reports Third Quarter Results
11. ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
Post Your Comments:
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: